A B S T R A C T In previous studies from this laboratory, human bone marrow hypoxanthine concentrations were found to average 7.1 MM, three times higher than plasma hypoxanthine concentrations measured simultaneously. To assess the significance of this finding, the relationship between hypoxanthine concentration and the rate of purine nucleotide synthesis by the de novo pathway was studied in normal human bone marrow mononuclear cells and in the human promyelocytic cell line, HL-60, in vitro. Utilizing a ['4C]formate incorporation technique, rates of total cellular de novo purine synthesis as well as rates of de novo adenine, de novo guanine, and thymine synthesis and incorporation into RNA and DNA were nmeasured as a function of hypoxanthine concentration. In normal human marrow cells, the rate of total de novo purine synthesis declined by 81%, while the rate of de novo adenine and de novo guanine synthesis and incorporation into macromolecules declined by 89 and 75%, respectively, when media hypoxanthine was increased from 0 to 10 uM. Similar results were seen in the HL-60 cell line. In contrast, rates of thymine synthesis and incorporation into DNA as well as overall rates of RNA and DNA synthesis did not change with varying media hypoxanthine concentrations. In addition, hypoxanthine salvage and incorporation into RNA and DNA was shown to progressively increase with increasing media hypoxanthine concentrations. These results indicate that physiologic concentrations of hypoxanthine are sufficient to regulate the rate of de novo purine synthesis in human bone marrow in vivo.
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of RNA and DNA, they regulate enzymatic activity as components of vitamins and cofactors, and they mediate energy transfer in the cell. This remarkable diversity of function emphasizes the fundamental importance of these compounds. Mammalian cells obtain purine nucleotides through two separate metabolic pathways: by de novo synthesis utilizing 5-phosphoribosyl-l-pyrophosphate (PRPP)' and glutamine or by salvage of extracellular purine bases and nucleosides. The regulation of these pathways has been the subject of numerous investigations, and an early observation was the strikingly low rate of de novo purine synthesis in several normal tissues, including intestine and bone marrow (1) (2) (3) (4) (5) . It has been suggested that these tissues have little, if any, capacity for de novo purine synithesis and are therefore dependent on the salvage of circulating purines (5, 6) . Recent studies in this laboratory have demonstrated a much higher concentration of the purine base hypoxanthine in human bone marrow than in plasma (7) . This observation has been confirmed by other investigators (8) . The average hypoxanthine concentration in eight bone marrow samples was 7.1 ,uM (range 1.9 to 20 MM), while that in venous plasma measured simultaneously was 2.0 MM (range 0.8 to 7.9 MM). Hypoxanthine has been shown to inhibit the de novo pathway of purine biosynthesis in human and animal cells in vitro (9) (10) (11) (12) (13) (14) (15) . Therefore, the apparent absence of de novo purine synthesis in bone marrow may have been the result of inhibition of this pathway by elevated concentrations of hypoxanthine.
In the present study, the effect of varying media concentrations of hypoxanthine on the rate of de novo purine synthesis was Research Products International Corp., Mount Prospect, IL) was added to each sample and the incubation continued for another 90 min. The incubation was terminated by centrifugation at 4°C for 4 min at 500 g. The cell pellet was resuspended in 2 ml of 0.4 N perchloric acid. The sample was then boiled in a water bath for 60 min and centrifuged for 10 min at 1,500 g. The supernatant (containing the free purine bases derived from both the acid-soluble and -insoluble purine pools) was applied to a 2.0 X 0.4-cm column of Dowex 50W-X4 cation exchange resin (Bio-Rad Laboratories, Richmond, CA) and washed with 15 ml of 0.1 N HCI. The purine bases were eluted with 5 ml of 5 N HCl. 1 ml of the eluate was added to 10 ml of Aquasol (New England Nuclear, Boston, MA) and quantitated by liquid scintillation counting.
Measurement of rates of de novo adenine, de novo guanine, and thymine synthesis and incorporation into DNA and RNA. In separate experiments, rates of ['4C]formate incorporation into the adenine, guanine, and thyrnine bases of newly synthesized RNA and DNA were measured. Cells were first incubated in varying concentrations of hypoxanthine and subsequently in ['4C]formic acid with termination of the incubation by centrifugation as described above. The cell pellet was resuspended in 2 ml of ice-cold 10% trichloroacetic acid and maintained on ice for 10 min. Samples were then centrifuged at 4°C for 10 min at 1,500 g and the supernatents discarded. The pellet was resuspended in 100
Al of 10 N perchloric acid and boiled in a water bath for 60 min. After cooling, the samples were diluted with 400 Ml of water and neutralized with 6 ml of alanine/freon as described by Khym (18) . A 150-AI aliquot of each resulting sample was then subjected to high pressure liquid chromatographic analysis of purine and pyrimidine base content using a method similar to that of Willis et al. (19) . Chromatography was performed using a Waters Associates liquid chromatograph at ambient temperature on a Bondapak C-18 reverse phase column (Waters Associates, Inc., Milford, MA) with a gradient developed from buffer A (10 mM potassium phosphate, pH 5.0) and buffer B (60% methanol in water). Absorbance was measured at 254 nM and 280 nM and peak areas determined with a Waters Associates model 730 data module. The bases were quantitated and elution times confirmed by comparison with pure standards. The adenine, guanine, and thymine peaks were collected separately and quantitated in 10-ml volumes of Aquasol by liquid scintillation counting.
Measurement of rates of purine salvage incorporation into RNA and DNA. In the HL-60 cell line, rates of hypoxanthine salvage and incorporation into RNA and DNA were determined with varying media hypoxanthine concentrations. 2 21.5 Ci/mmol; New England Nuclear) was added and the incubation continued for 30 min. The incubation was terminated by centrifugation at 4°C for 5 min at 500 g and the supernatent discarded. The cell pellet was resuspended in 2 ml of ice-cold 10% trichloroacetic acid and maintained on ice for 20 min. The precipitate was collected on Whatman GF/C filter paper, washed, and quantitated by liquid scintillation counting as described above.
RESULTS
Using a ['4C]formate labeling technique, rates of total cellular de novo purine synthesis were measured in normal human bone marrow and HL-60 cells in the presence of varying media hypoxanthine concentrations. Combined results for three experiments using human marrow with duplicate or triplicate samples are shown in Fig. 1 . As the concentration of hypoxanthine was increased from 0.1 to 10 AM, total cellular de novo purine synthesis progressively declined from 82 to 19% of that seen when no hypoxanthine was added to the media. Combined results for three experiments with triplicate samples utilizing the HL-60 cell line are also shown in Fig. 1 , and are similar to those for human marrow. The ID50 concentrations of hypoxanthine estimated from these data are 0.4 and 0.8 uM for human marrow and HL-60, respectively. These hypoxanthine concentrations are well below those found in humnan bone marrow in vivo (7) .
In other experiments, the effect of media hypoxanthine concentration on the amount of adenine, guanine, and thymine synthesized and subsequently incorporated in RNA and DNA macromolecules was examined. For 
DISCUSSION
Despite extensive investigation of the pathways of cellular purine metabolism, the precise controls governing purine synthesis, release, and degradation in mammalian tissues remain poorly understood. In early studies by Abrams and Goldfinger (1), Trotter (3) , and Lajtha and Vane (6), rates of de novo purine synthesis were found to be very low in bone marrow tissues despite high rates of purine turnover, suggesting that these cells were dependent upon the salvage of circulating purines. This view continues to be accepted by many authors today (20, 21) , but the details of such a system of purine salvage and reutilization have not been fully elucidated. Recently, high levels of hypoxanthine have been found in human bone marrow (7, 8) , and in the present study the role of hypoxanthine in bone marrow purine metabolism was investigated.
Our results demonstrate that physiologic concentrations of hypoxanthine inhibit de novo purine synthesis in both normal human bone marrow mononuclear cells and in a related cell line, HL-60. In HL-60 cells, hypoxanthine was shown to be preferentially utilized for purine nucleotide synthesis by the salvage pathway.
Rates of RNA and DNA synthesis appeared to remain constant over a wide range of hypoxanthine concentrations, demonstrating the capacity for rapid adjustment in the balance between purine de novo synthesis and salvage in these cells. These results suggest a key regulatory role for hypoxanthine in purine metabolism and explain the low rates of de novo purine synthesis previously observed in bone marrow tissues. They are supported by similar observations of hypoxanthine inhibition of de novo purine synthesis in cultured human solid tumor cells (10) , in freshly harvested human acute leukemia cells (9) , and in a human lymphoblastic cell line (12, 13) . The proposed mechanisms of this effect include (a) nucleotide feedback inhibition of PRPP amido-transferase at the rate-limiting step of de novo purine synthesis (15, 20) ; (b) competition for PRPP, which is required for both hypoxanthine salvage in the phosphoribosyltransferase reaction and for de novo purine synthesis at the PRPP amido-transferase step (20) ; and (c) nucleotide feedback inhibition of PRPP synthetase, the first enzyme in the de novo purine synthesis pathway (15) . Although one or a combination of these mechanisms may explain the inhibition of de novo purine synthesis by hypoxanthine, the site of production and mechanism of transport of the hypoxanthine found in high concentration in human bone marrow remains unknown. Bertles and Beck (22) noted that reticulocytes release hypoxanthine and other purines during maturation and proposed that these materials might be utilized by neighboring cells. In view of the low rate of de novo purine synthesis in bone marrow tissue (1-4), however, it is likely that extracellular hypoxanthine originates elsewhere. In this regard, Lajtha and Vane (6) (23, 24) . In other studies, erythrocytes were implicated as a vehicle for purine transport from the liver to peripheral tissues (25) . The major purine released from rabbit erythrocytes has been identified as hypoxanthine (26, 27) , suggesting that this base may be the purine transferred to peripheral tissues by the erythrocyte. In addition, hypoxanthine has been shown to be rapidly and efficiently cleared from plasma by the liver and hepatic adenosine release has been shown to be proportional to the concentration of hypoxanthine perfusing the liver (24) . These historical observations and the data presented in this report are consistent with the following hypothesis. Adenosine, synthesized in the liver, may be taken up by erythrocytes in hepatic sinusoids, transported to peripheral tissues, and released in the form of hypoxanthine. This hypoxanthine may then be utilized by tissues such as bone marrow and intestine for purine nucleotide synthesis through the salvage pathway. Hypoxanthine not utilized in this manner, as well as that originating from purine catabolism, may eventually be returned to the liver where it is efficiently cleared from the plasma and reutilized or excreted. This hypothesis establishes a mechanism for purine homeostasis. It also explains the low rates of de novo purine synthesis and the high concentrations of hypoxanthine found in bone marrow tissues, and is supported by the results of this investigation suggesting a regulatory role for hypoxanthine in human bone marrow purine metabolism.
The ability of hypoxanthine to regulate purine synthesis also has significance for cancer chemotherapy. In a recent report, hypoxanthine (at concentrations found in the supernatent of human bone marrow or in the plasma of patients with acute leukemia receiving allopurinol) was shown to significantly reduce the cytotoxicity of several purine antimetabolites in vitro using a clonogenic assay technique (7) . These results suggest that fluctuations in hypoxanthine concentration may also markedly influence the toxicity of these purine antimetabolites in human bone marrow. Further information is needed on the metabolism of hypoxanthine and the regulation of levels of this purine in plasma and bone marrow.
